The worldwide market for kinase inhibitors for clinical use will reach $4.63 billion in 2005 and will rise at an average annual growth rate (AAGR) of 20.6% to $11.8 billion by 2010.
Receptor tyrosine kinase inhibitors comprise 49.8% of the total market in 2005 and are projected to grow at an AAGR of 26.6% to account for 63.7% of the total in 2010.
Nonreceptor tyrosine kinase inhibitors, consisting of BCR-Abl kinase inhibitor, reached sales of $1.86 billion in 2005. They are projected to increase at an AAGR of 13.7% to reach $3.56 billion in 2010.
The major disease application for kinase inhibitors is oncology that comprised nearly 90% of kinase inhibitor sales in 2005 and is expected to grow at an AAGR of 21.5%.
Human protein kinases are intriguing drug targets, in part because they regulate a wide variety of signaling pathways and include over 500 distinct protein molecules. Synthetic inhibitors of protein kinases include small molecules that may be easily administered as oral therapeutic compounds. These inhibitors can rapidly and often specifically alter the activation state of a target kinase. They further have significant potential in the clinical treatment of major diseases including cancer, heart disease, inflammatory disorders, diabetes, macular degeneration, and neurological disorders.
This BCC study determines the current status of the kinase inhibitor industry and assesses its growth potential. Only a handful such therapeutics have entered clinical use as of 2005. For each, BCC examined the drug development process, major challenges and achievements and where applicable, the projected market for each of these drugs through 2010.
Of particular interest are up-and-coming kinase inhibitors in clinical trials and preclinical development. Leading candidates are identified in each kinase inhibitor class by molecular target and by disease application. The result is a comprehensive analysis of the current market and its future direction.
SCOPE OF STUDY
The report contains:
- A thorough review of the technologies employed in the kinase inhibitor
- Analysis of the evidence of efficacy and technical limitations of each kinase inhibitor type in clinical use
- Analysis of the current market status and growth forecasts through 2010 for each kinase inhibitor
- Examination of the potential for additional novel applications
- Discussion of the role of government regulations, recent patents and factors affecting the industry worldwide
- Analysis of how the development of new kinase inhibitors is translating into new medical therapies for specific disease targets.
The market assessments provided have been assembled based on publicly available information from January 2002 up to and including August 2005. The base year for this report is 2005 and forecast data are provided through 2009. In cases where data for 2005 were not available, figures were extrapolated from 2004 statistics, half-year figures for 2005 and historical trends between 2001 and 2004. Market figures are based on current dollars and inflation is not computed into the projection figures. Interviews were also used to adjust market size estimates, as well as to formulate market projections.
The field of kinase inhibitor development is still immature and the reader is cautioned to use the report data as a guide to assess trends, developments and challenges that the industry faces.
The information contained in this report has been assembled from primary and secondary data. Primary research was conducted via telephone interviews with selected industry professionals, research scientists, and laboratory heads to discover the most recent developments in their fields of interest. Secondary data was collected via a comprehensive search of the scientific, peer-reviewed literature, clinical trial reports and databases, industry trade media, company websites, annual reports and industry press releases.
Amy Brock, Ph.D. has over ten years of research experience working at the interface of the biological sciences, bioengineering and biophysics. Trained at the Massachusetts Institute of Technology and Harvard University, she holds a B.S. and Ph.D. in biomedical science. She is the author of B-204, Pharmacogenomics: New Technologies in the Development of Personalized Therapies.